JP2008520186A - 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体 - Google Patents

哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体 Download PDF

Info

Publication number
JP2008520186A
JP2008520186A JP2007533961A JP2007533961A JP2008520186A JP 2008520186 A JP2008520186 A JP 2008520186A JP 2007533961 A JP2007533961 A JP 2007533961A JP 2007533961 A JP2007533961 A JP 2007533961A JP 2008520186 A JP2008520186 A JP 2008520186A
Authority
JP
Japan
Prior art keywords
antibody
eag1
cancer
derivative
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007533961A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520186A5 (enExample
Inventor
ヴァルター・シュテューマー
ヘンドリク・クネットゲン
デビッド・ゴメス−バレラ
ルイス・アー・パルド
ミケ・ローテ
エステル・ツヴィック−ヴァラッシュ
ケルスティン・デーネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
U3 PHARMA AG
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
U3 PHARMA AG
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U3 PHARMA AG, Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical U3 PHARMA AG
Publication of JP2008520186A publication Critical patent/JP2008520186A/ja
Publication of JP2008520186A5 publication Critical patent/JP2008520186A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2007533961A 2004-10-01 2005-10-04 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体 Pending JP2008520186A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04023489 2004-10-01
PCT/EP2005/010671 WO2006037604A1 (en) 2004-10-01 2005-10-04 Novel antibodies directed to the mammalian eag1 ion channel protein

Publications (2)

Publication Number Publication Date
JP2008520186A true JP2008520186A (ja) 2008-06-19
JP2008520186A5 JP2008520186A5 (enExample) 2009-05-28

Family

ID=34926818

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007533961A Pending JP2008520186A (ja) 2004-10-01 2005-10-04 哺乳類ｅａｇ１イオンチャネルタンパク質に対する新規の抗体

Country Status (8)

Country Link
US (1) US7910100B2 (enExample)
EP (1) EP1805222B1 (enExample)
JP (1) JP2008520186A (enExample)
AT (1) ATE497508T1 (enExample)
AU (1) AU2005291486A1 (enExample)
CA (1) CA2582683A1 (enExample)
DE (1) DE602005026219D1 (enExample)
WO (1) WO2006037604A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500972A (ja) * 2008-08-20 2012-01-12 ニューヨーク ブラッド センター， インコーポレイテッド 高解像度デジタル撮像、分染および自動化実験室システムの使用による、ｃｆｕアッセイのための高スループットシステム
JP2013511288A (ja) * 2009-11-24 2013-04-04 アレシア・バイオセラピューティクス・インコーポレーテッド 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2007064972A2 (en) 2005-11-30 2007-06-07 Abbott Laboratories Monoclonal antibodies against amyloid beta protein and uses thereof
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
SG173385A1 (en) 2006-07-14 2011-08-29 Ac Immune S A Ch Humanized antibody against amyloid beta
EP2051997B1 (en) * 2006-08-22 2015-03-18 G2 Inflammation Pty Ltd Anti-c5ar antibodies with improved properties
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US7858752B2 (en) 2006-12-05 2010-12-28 Abbott Laboratories Recombinant antibodies against hepatitis C virus and methods of obtaining and using same
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
JP5142265B2 (ja) * 2007-05-28 2013-02-13 独立行政法人産業技術総合研究所 抗モータリン抗体のパラトープ及びエピトープ
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CA2690568A1 (en) * 2007-06-20 2008-12-24 Schering Corporation Joint destruction biomarkers for anti-il-17a therapy of inflammatory joint disease
PT2238166E (pt) 2007-10-05 2014-02-11 Genentech Inc Utilização do anticorpo anti-amilóide beta em doenças oculares
US20100291108A1 (en) * 2007-10-16 2010-11-18 Arie Abo Antibodies to irem-1
JP5769969B2 (ja) 2007-11-12 2015-08-26 ユー３・ファーマ・ゲーエムベーハー Ａｘｌ抗体
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
NZ588554A (en) * 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256250B2 (en) * 2008-06-03 2013-05-30 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
SG191625A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
SG192489A1 (en) * 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8512677B2 (en) * 2009-04-27 2013-08-20 Case Western Reserve University Pyro-glutamate Aβ targeting agents
EP2270053A1 (en) * 2009-05-11 2011-01-05 U3 Pharma GmbH Humanized AXL antibodies
WO2010130751A1 (en) * 2009-05-11 2010-11-18 U3 Pharma Gmbh Humanized axl antibodies
FR2945538B1 (fr) * 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
CN102612524A (zh) * 2009-09-01 2012-07-25 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
PL3023438T3 (pl) 2009-09-03 2020-07-27 Merck Sharp & Dohme Corp. Przeciwciała anty-gitr
CN102482701B (zh) * 2009-09-16 2015-05-13 免疫医疗公司 I类抗-cea抗体及其使用
PH12012500691A1 (en) * 2009-10-15 2012-11-12 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
RU2607368C2 (ru) 2010-07-30 2017-01-10 Ац Иммуне С.А. Безопасные и функциональные гуманизированные антитела
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * Inmunoglobulinas de dominio variable doble y usos de las mismas.
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AR083705A1 (es) * 2010-11-04 2013-03-13 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
BR112014015851A2 (pt) 2011-12-30 2019-09-24 Abbvie Inc proteínas de ligação específicas duplas direcionadas contra il-13 e/ou il-17
AU2013224591A1 (en) 2012-02-22 2014-07-24 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an EGFR inhibitor to treat cancer
AU2013237949A1 (en) 2012-03-28 2014-11-13 University Of Houston System Methods and software for screening and diagnosing skin lesions and plant diseases
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
PE20151179A1 (es) 2012-11-01 2015-09-12 Abbvie Inc Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas
SG10201707855YA (en) * 2013-03-13 2017-10-30 Prothena Biosciences Ltd Tau immunotherapy
JP2016522793A (ja) 2013-03-15 2016-08-04 アッヴィ・インコーポレイテッド ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質
JPWO2014175444A1 (ja) * 2013-04-26 2017-02-23 千葉県 抗ｎｌｒｒ１抗体
MX2016007691A (es) 2013-12-12 2017-05-01 Umc Utrecht Holding Bv "moleculas similares a la inmunoglobulina dirigidas contra la "fibronectina-eda.
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
EP3307784B1 (en) * 2015-06-10 2021-12-22 National Research Council of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
PE20190208A1 (es) 2016-05-02 2019-02-07 Prothena Biosciences Ltd Anticuerpos que reconocen tau
JP7481726B2 (ja) 2016-05-02 2024-05-13 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
PL3452507T3 (pl) 2016-05-02 2023-01-09 Prothena Biosciences Limited Immunoterapia tau
RU2019100102A (ru) 2016-06-16 2020-07-16 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити Гуманизированные и химерные моноклональные антитела против cd81
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN113544149B (zh) 2019-03-03 2024-11-15 普罗塞纳生物科学有限公司 识别tau的抗体
CN110616192B (zh) * 2019-08-09 2021-11-09 无锡傲锐东源生物科技有限公司 一种抗人神经丝轻链(nefl)的单克隆抗体及其应用
US12486321B2 (en) 2020-01-21 2025-12-02 Tavotek Biotechnology (Jiangsu) Co., Ltd Agents that interfere with IL-1BETA receptor signalling
WO2021247805A1 (en) * 2020-06-05 2021-12-09 The Johns Hopkins University Humanized antibodies directed against kcnk9
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512029A (ja) * 1998-04-21 2002-04-23 マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー．ファウ． ヒトｋ＋イオンチャンネルおよびその治療的適用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
EP0804070B1 (en) 1993-03-09 2000-05-24 Genzyme Corporation Process of isolation of proteins from milk
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6203822B1 (en) 1996-09-03 2001-03-20 University Of Iowa Research Foundation Gallium-containing compounds for the treatment of infections caused by intracellular pathogens and pathogens causing chronic pulmonary infection
HUP0101160A2 (hu) 1998-04-03 2001-08-28 Chugai Seiyaku Kabushiki Kaisha Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
CA2341029A1 (en) 1998-08-17 2000-02-24 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20040254108A1 (en) * 2003-06-13 2004-12-16 Jing Ma Preparation and application of anti-tumor bifunctional fusion proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002512029A (ja) * 1998-04-21 2002-04-23 マックス−プランク−ゲゼルシャフト ツール フォルデルング デル ヴィッセンシャフテン エー．ファウ． ヒトｋ＋イオンチャンネルおよびその治療的適用

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012500972A (ja) * 2008-08-20 2012-01-12 ニューヨーク ブラッド センター， インコーポレイテッド 高解像度デジタル撮像、分染および自動化実験室システムの使用による、ｃｆｕアッセイのための高スループットシステム
JP2013511288A (ja) * 2009-11-24 2013-04-04 アレシア・バイオセラピューティクス・インコーポレーテッド 抗クラステリン抗体及び抗原結合フラグメント並びに腫瘍容積を低減するためのそれらの使用
US9512211B2 (en) 2009-11-24 2016-12-06 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume

Also Published As

Publication number Publication date
EP1805222A1 (en) 2007-07-11
WO2006037604A1 (en) 2006-04-13
US7910100B2 (en) 2011-03-22
CA2582683A1 (en) 2006-04-13
DE602005026219D1 (de) 2011-03-17
ATE497508T1 (de) 2011-02-15
AU2005291486A1 (en) 2006-04-13
EP1805222B1 (en) 2011-02-02
US20090028851A1 (en) 2009-01-29

Similar Documents

Publication Publication Date Title
US7910100B2 (en) Antibodies directed to the mammalian EAG1 ion channel protein
JP6728264B2 (ja) 抗ｈｅｒ２抗体及びその結合体
CN101939336B (zh) Axl抗体
CN102421802B (zh) 人源化的axl抗体
CN1922199B (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
KR102048718B1 (ko) 항-cxcr4 항체 및 항체-약물 접합체
RU2659094C2 (ru) Антигенсвязывающий белок и его применение в качестве продукта для адресной доставки при лечении рака
JP2019112403A (ja) 抗ｈｅｒ２抗体−薬物コンジュゲート
KR20180130574A (ko) 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
CA3050672A1 (en) Dll3-binding antibodies and drug conjugates thereof to treat cancer
CN107074948A (zh) 结合axl的抗体
KR20140008308A (ko) 신규한 egfr-결합 분자 및 이의 면역컨쥬게이트
KR20150063565A (ko) Her3의 베타-헤어핀 및 her4의 베타-헤어핀에 결합하는 항-her3/her4 항원 결합 단백질
KR20150064205A (ko) Her3의 베타-헤어핀에 결합하는 her3 항원 결합 단백질
CN101242855A (zh) Ca6抗原特异性细胞毒性偶联物及其应用方法
KR20190068550A (ko) 항-c met 항체-세포독성 약물 컨쥬게이트의 의학적 용도
CN110799211B (zh) 特异性识别丛蛋白-信号素-整合素结构域的抗ron单克隆抗体的药物呈递作用及其在肿瘤治疗中的应用
CN120981485A (zh) 抗ptk7抗体及其用途
JP2023549925A (ja) 抗ｃｄ４８抗体、抗体薬物コンジュゲート及びその使用
JP2025542294A (ja) Ａｌｐｐ特異的バリアント抗原結合分子
JP2026501556A (ja) 抗体薬物複合体
WO2024210437A1 (ko) 항-bcam 항체 및 항체-약물 접합체
RU2802211C2 (ru) Конъюгат анти-her3 антитело-лекарственное средство
HK40115552A (zh) 抗ptk7抗体及其用途
HK1211035A1 (en) ANTIBODIES TO INTEGRIN αVβ6 AND USE OF SAME TO TREAT CANCER

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090410

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110419

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110818

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110726

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110825

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110920

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110928

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120124